<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01901146</url>
  </required_header>
  <id_info>
    <org_study_id>20120283</org_study_id>
    <secondary_id>2012-004319-29</secondary_id>
    <nct_id>NCT01901146</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer</brief_title>
  <acronym>Lilac</acronym>
  <official_title>A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to compare the effectiveness and safety of ABP 980
      against trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive
      early breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 29, 2013</start_date>
  <completion_date type="Actual">January 27, 2017</completion_date>
  <primary_completion_date type="Actual">May 5, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Pathologic Complete Response</measure>
    <time_frame>3 to 7 weeks after the last dose of study drug in the neoadjuvant phase</time_frame>
    <description>Pathologic complete response (pCR) was defined as the absence of invasive tumor cells in the breast tissue and in axillary lymph nodes, regardless of residual ductal carcinoma in situ (DCIS).
Participants underwent a lumpectomy or mastectomy with sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND) within 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase. The pathology evaluation of surgical specimens for pCR analysis was conducted by local laboratories at the study sites.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Pathologic Complete Response in Breast Tissue Only</measure>
    <time_frame>3 to 7 weeks after the last dose of study drug in the neoadjuvant phase</time_frame>
    <description>Pathologic complete response (pCR) was defined as the absence of invasive tumor cells in the breast tissue, regardless of residual ductal carcinoma in situ (DCIS).
Participants underwent a lumpectomy or mastectomy with sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND) within 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase. The pathology evaluation of surgical specimens for pCR analysis was conducted by local laboratories at the study sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Pathologic Complete Response in Breast Tissue and Axillary Lymph Nodes and Absence of DCIS</measure>
    <time_frame>3 to 7 weeks after the last dose of study drug in the neoadjuvant phase</time_frame>
    <description>Pathological complete response was defined as the absence of invasive tumor cells in the breast tissue and axillary lymph node(s) and absence of residual DCIS.
Participants underwent a lumpectomy or mastectomy with sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND) within 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase. The pathology evaluation of surgical specimens for pCR analysis was conducted by local laboratories at the study sites.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">725</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ABP 980</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received ABP 980 at an initial dose of 8 mg/kg by intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase.
Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase.
After surgery (adjuvant phase) participants continued receiving 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trastuzumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received trastuzumab at an initial dose of 8 mg/kg IV infusion, then 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase.
Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase.
After surgery (adjuvant phase) participants were re-randomized to either continue receiving 6 mg/kg trastuzumab IV Q3W or transition to 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABP 980</intervention_name>
    <description>ABP 980 was administered at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.</description>
    <arm_group_label>ABP 980</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab was administered at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.</description>
    <arm_group_label>Trastuzumab</arm_group_label>
    <other_name>Herceptin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care).</description>
    <arm_group_label>ABP 980</arm_group_label>
    <arm_group_label>Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection</intervention_name>
    <arm_group_label>ABP 980</arm_group_label>
    <arm_group_label>Trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females ≥ 18 years of age

          -  Histologically confirmed invasive breast cancer

          -  Planning for surgical resection of breast tumor and sentinel node or axillary lymph
             node resection

          -  Planning neoadjuvant chemotherapy

          -  HER2 positive disease

          -  Measurable disease in the breast after diagnostic biopsy, defined as longest diameter
             ≥ 2.0 cm

          -  Known estrogen receptor (ER) and progesterone receptor (PR) hormone receptor status at
             study entry

          -  Normal bone marrow function

          -  Normal hepatic function

          -  Normal renal function

          -  Subjects must sign an Institutional Review Board/Ethics Committee (IRB/EC)-approved
             informed consent form before any study specific procedures

        Inclusion Criteria for Randomization:

          -  Left ventricular ejection fraction (LVEF) of ≥55% by 2D echocardiogram

          -  Complete all 4 cycles of run-in chemotherapy

        Exclusion Criteria:

          -  Bilateral breast cancer

          -  Presence of known metastases

          -  Received prior treatment, including chemotherapy, biologic therapy, radiation or
             surgery with the exception of diagnostic biopsy for primary breast cancer

          -  Other concomitant active malignancy or history of malignancy in the past 5 years
             except treated basal cell carcinoma of the skin or carcinoma in situ of the cervix

          -  Pre-existing clinically significant (≥ grade 2) peripheral neuropathy

          -  Any history of documented or current congestive heart failure, current high-risk
             uncontrolled arrhythmias, current angina pectoris requiring a medicinal product,
             current clinically significant valvular disease, current evidence of transmural
             infarction on electrocardiogram (ECG), or current poorly controlled hypertension

          -  Severe dyspnea at rest requiring supplementary oxygen therapy

          -  History of positivity for hepatitis B surface antigen, hepatitis C virus, or human
             immunodeficiency virus (HIV)

          -  Recent infection requiring a course of systemic anti-infectives that were completed ≤
             14 days before enrollment (with the exception of uncomplicated urinary tract
             infection)

          -  Woman of childbearing potential who is pregnant or is breast feeding

          -  Woman of childbearing potential who is not consenting to use highly effective methods
             of birth control (eg, true abstinence [periodic abstinence (eg calendar ovulation,
             symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of
             contraception], sterilization, or other non-hormonal forms of contraception) during
             treatment and for at least 7 months after the last administration of the protocol
             specified treatment

          -  Currently receiving treatment in another investigational device or drug study, or less
             than 30 days since ending treatment on another investigational device or drug study

          -  Other investigational procedures while participating in this study are excluded

          -  Subject has known sensitivity to any of the products to be administered during the
             study, including mammalian cell derived drug products, trastuzumab, murine proteins,
             or to any of the excipients

          -  Subject previously has enrolled and/or has been randomized in this study

          -  Subject likely to not be available to complete all protocol required study visits or
             procedures

          -  History or evidence of any other clinically significant disorder, condition or disease
             (with the exception of those outlined above) that, in the opinion of the Investigator
             or Amgen physician, if consulted, would pose a risk to subject safety or interfere
             with the study evaluation, procedures or completion
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brest</city>
        <zip>224027</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grodno</city>
        <zip>230017</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minsk</city>
        <zip>220013</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minsk</city>
        <zip>223040</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41820-021</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ijuí</city>
        <state>RIO Grande DO SUL</state>
        <zip>98700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RIO Grande DO SUL</state>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaú</city>
        <state>SAO Paulo</state>
        <zip>17210-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo André</city>
        <state>SAO Paulo</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <state>SAO Paulo</state>
        <zip>04039-004</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <state>Sofiya</state>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Veliko Tarnovo</city>
        <state>Veliko Turnovo</state>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Temuco</city>
        <state>Cautín</state>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>8360160</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fürstenwalde</city>
        <state>Brandenburg</state>
        <zip>15517</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-westfalen</state>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bottrop</city>
        <state>Nordrhein-westfalen</state>
        <zip>46236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heraklion</city>
        <state>Crete</state>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <state>Nea Efkarpia</state>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <state>Hajdu-bihar</state>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szolnok</city>
        <state>Jasz-nagykun-szolnok</state>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyíregyháza</city>
        <state>Szabolcs-szatmar-bereg</state>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szekszárd</city>
        <state>Tolna</state>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Fermo della Battaglia</city>
        <state>Como</state>
        <zip>22040</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bari</city>
        <zip>74124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LEON</state>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Luis Potosí</city>
        <state>SAN LUIS Potosi</state>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Queretaro</city>
        <zip>76090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toluca, Estado De Mexico</city>
        <zip>50180</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-792</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <state>Lubelskie</state>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>03-291</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdańsk</city>
        <state>Pomorskie</state>
        <zip>80-219</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rybnik</city>
        <state>Slaskie</state>
        <zip>44-217</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <state>Wielkopolskie</state>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <state>Wielkopolskie</state>
        <zip>61-485</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Cluj</state>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ploiesti</city>
        <state>Prahova</state>
        <zip>100337</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300595</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasov</city>
        <zip>500091</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj</city>
        <zip>400058</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Obninsk</city>
        <state>Kaluzhskaya</state>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saransk</city>
        <state>Mordovia</state>
        <zip>430032</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow Region</city>
        <state>Moscow</state>
        <zip>143423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arkhangelsk</city>
        <state>Primorskiy</state>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <state>Yaroslavlr</state>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chelaybinsk</city>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603081</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195271</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sochi</city>
        <zip>354057</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A Coruña</city>
        <state>LA Coruna</state>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lérida</city>
        <state>Lleida</state>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28921</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28220</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <state>Kiev</state>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uzhgorod</city>
        <state>Transcarpathia</state>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lutsk</city>
        <state>Volyn</state>
        <zip>43018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49055</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lviv</city>
        <zip>79031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69040</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Peterborough</city>
        <state>England</state>
        <zip>PE3 9GZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Slovakia</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>May 20, 2013</study_first_submitted>
  <study_first_submitted_qc>July 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2013</study_first_posted>
  <results_first_submitted>June 18, 2019</results_first_submitted>
  <results_first_submitted_qc>June 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2019</results_first_posted>
  <disposition_first_submitted>April 6, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>April 6, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 10, 2017</disposition_first_posted>
  <last_update_submitted>June 18, 2019</last_update_submitted>
  <last_update_submitted_qc>June 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Epidermal Growth Factor Receptor 2 (HER2)</keyword>
  <keyword>Positive Early Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 123 sites in 20 countries from April 2013 to January 2017. The study consisted of a neoadjuvant treatment phase for 4 cycles, surgery, and adjuvant treatment for up to one year from the first day of study drug administration in the neoadjuvant phase.</recruitment_details>
      <pre_assignment_details>Enrolled patients received run-in chemotherapy consisting of epirubicin and cyclophosphamide every 3 weeks for 4 cycles. After the run-in, participants with adequate cardiac function were randomized. Randomization was stratified by tumor stage, nodal status, hormone receptor status, planned paclitaxel dosing schedule, and geographic region.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ABP 980</title>
          <description>Participants received ABP 980 at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles.</description>
        </group>
        <group group_id="P2">
          <title>Trastuzumab</title>
          <description>Participants received trastuzumab at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles.</description>
        </group>
        <group group_id="P3">
          <title>ABP 980/ABP 980</title>
          <description>After surgery, participants initially randomized to ABP 980 continued to receive ABP 980 at a dose of 6 mg/kg IV infusion Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase.</description>
        </group>
        <group group_id="P4">
          <title>Trastuzumab/Trastuzumab</title>
          <description>After surgery, participants originally randomized to trastuzumab were re-randomized and continued to receive trastuzumab at a dose of 6 mg/kg IV infusion Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase.</description>
        </group>
        <group group_id="P5">
          <title>Trastuzumab/ABP 980</title>
          <description>After surgery, participants originally randomized to trastuzumab were re-randomized and switched to receive ABP 980 at a dose of 6 mg/kg IV infusion Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Neoadjuvant Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="364"/>
                <participants group_id="P2" count="361"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="358">Indicates participants who completed surgery</participants>
                <participants group_id="P2" count="347">Indicates participants who completed surgery</participants>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression or Recurrence</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Requirement for Alternative Therapy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Adjuvant Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="349">Nine participants discontinued the study after surgery but before entering adjuvant phase.</participants>
                <participants group_id="P4" count="171">Two participants discontinued the study after surgery but before entering adjuvant phase.</participants>
                <participants group_id="P5" count="171">Three participants discontinued the study after surgery but before entering adjuvant phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="323"/>
                <participants group_id="P4" count="164"/>
                <participants group_id="P5" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression or Recurrence</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ABP 980</title>
          <description>Participants received ABP 980 at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles.</description>
        </group>
        <group group_id="B2">
          <title>Trastuzumab</title>
          <description>Participants received trastuzumab at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="364"/>
            <count group_id="B2" value="361"/>
            <count group_id="B3" value="725"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.8" spread="10.72"/>
                    <measurement group_id="B2" value="52.7" spread="11.29"/>
                    <measurement group_id="B3" value="52.7" spread="11.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 50 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="274"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 50 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="227"/>
                    <measurement group_id="B3" value="451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="364"/>
                    <measurement group_id="B2" value="361"/>
                    <measurement group_id="B3" value="725"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="331"/>
                    <measurement group_id="B2" value="333"/>
                    <measurement group_id="B3" value="664"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="332"/>
                    <measurement group_id="B2" value="324"/>
                    <measurement group_id="B3" value="656"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not allowed to collect</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor Stage</title>
          <description>In the Tumor Node Metastasis (TNM) staging system, a &quot;T&quot; followed by a number shows the size of the tumor. Less than T4 indicates a tumor that is 5 cm or less. T4 indicates the tumor is any size, but has spread beyond the breast tissue to the chest wall and/or skin.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; T4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="282"/>
                    <measurement group_id="B2" value="281"/>
                    <measurement group_id="B3" value="563"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Axilla Lymph Node Involvement</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="277"/>
                    <measurement group_id="B2" value="266"/>
                    <measurement group_id="B3" value="543"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hormone Receptor Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Estrogen and/or progesterone receptor positive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="265"/>
                    <measurement group_id="B2" value="268"/>
                    <measurement group_id="B3" value="533"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Estrogen and progesterone receptor negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Paclitaxel Dosing Schedule</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Every 3 weeks</title>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                    <measurement group_id="B2" value="258"/>
                    <measurement group_id="B3" value="514"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Every week</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Geographic Region</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Eastern Europe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="271"/>
                    <measurement group_id="B2" value="273"/>
                    <measurement group_id="B3" value="544"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Western Europe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Pathologic Complete Response</title>
        <description>Pathologic complete response (pCR) was defined as the absence of invasive tumor cells in the breast tissue and in axillary lymph nodes, regardless of residual ductal carcinoma in situ (DCIS).
Participants underwent a lumpectomy or mastectomy with sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND) within 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase. The pathology evaluation of surgical specimens for pCR analysis was conducted by local laboratories at the study sites.</description>
        <time_frame>3 to 7 weeks after the last dose of study drug in the neoadjuvant phase</time_frame>
        <population>The pCR evaluable population, which included all randomized participants who received any amount of study drug, underwent the surgery, and had a non-missing evaluable pCR assessment from the local laboratory evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>ABP 980</title>
            <description>Participants received ABP 980 at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Trastuzumab</title>
            <description>Participants received trastuzumab at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Pathologic Complete Response</title>
          <description>Pathologic complete response (pCR) was defined as the absence of invasive tumor cells in the breast tissue and in axillary lymph nodes, regardless of residual ductal carcinoma in situ (DCIS).
Participants underwent a lumpectomy or mastectomy with sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND) within 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase. The pathology evaluation of surgical specimens for pCR analysis was conducted by local laboratories at the study sites.</description>
          <population>The pCR evaluable population, which included all randomized participants who received any amount of study drug, underwent the surgery, and had a non-missing evaluable pCR assessment from the local laboratory evaluation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="358"/>
                <count group_id="O2" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0"/>
                    <measurement group_id="O2" value="40.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The clinical equivalence between ABP 980 and trastuzumab was first evaluated by comparing the 2-sided 90% confidence interval (CI) of the Risk Difference (RD; ABP 980 - Trastuzumab) of pCR between ABP 980 and trastuzumab with a fixed margin of (-13%, 13%), estimated using a generalized linear model adjusted for stratification factors tumor (T)-stage, nodal status, hormone receptor status, planned paclitaxel dosing schedule, and geographic region.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The clinical equivalence between ABP 980 and trastuzumab was first evaluated by comparing the 2-sided 90% CI of the risk difference of pCR between ABP 980 and trastuzumab with a fixed margin of (-13%, 13%).</non_inferiority_desc>
            <p_value>0.0508</p_value>
            <method>Generalized linear model</method>
            <method_desc>Generalized linear model adjusted for the randomization stratification factors.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>7.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>13.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>If the test of equivalence on the RD of pCR was successful, then equivalence was tested on the Risk Ratio (RR; ABP 980 / Trastuzumab) of pCR at a 2-sided significance level of 0.05 by comparing the 2-sided 90% CI of the RR of pCR between ABP 980 and trastuzumab, estimated using a generalized linear model adjusted for stratification factors: tumor (T)-stage, nodal status, hormone receptor status, planned paclitaxel dosing schedule, and geographic region.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the test of equivalence on the RD of pCR was successful, then equivalence was tested on the risk ratio of pCR at a 2-sided significance level of 0.05 by comparing the 2-sided 90% CI of the RR of pCR between ABP 980 and trastuzumab estimated using a generalized linear model adjusted for stratification factors, with the margin of (0.7586, 1/0.7586). If the test of equivalence on the RD was not successful, the RR of pCR and 90% CI were considered to be descriptive.</non_inferiority_desc>
            <p_value>0.0430</p_value>
            <method>Generalized linear model</method>
            <method_desc>Generalized linear model adjusted for the randomization stratification factors.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.1877</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0327</ci_lower_limit>
            <ci_upper_limit>1.3660</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Pathologic Complete Response in Breast Tissue Only</title>
        <description>Pathologic complete response (pCR) was defined as the absence of invasive tumor cells in the breast tissue, regardless of residual ductal carcinoma in situ (DCIS).
Participants underwent a lumpectomy or mastectomy with sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND) within 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase. The pathology evaluation of surgical specimens for pCR analysis was conducted by local laboratories at the study sites.</description>
        <time_frame>3 to 7 weeks after the last dose of study drug in the neoadjuvant phase</time_frame>
        <population>pCR evaluable population</population>
        <group_list>
          <group group_id="O1">
            <title>ABP 980</title>
            <description>Participants received ABP 980 at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Trastuzumab</title>
            <description>Participants received trastuzumab at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Pathologic Complete Response in Breast Tissue Only</title>
          <description>Pathologic complete response (pCR) was defined as the absence of invasive tumor cells in the breast tissue, regardless of residual ductal carcinoma in situ (DCIS).
Participants underwent a lumpectomy or mastectomy with sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND) within 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase. The pathology evaluation of surgical specimens for pCR analysis was conducted by local laboratories at the study sites.</description>
          <population>pCR evaluable population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="358"/>
                <count group_id="O2" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1"/>
                    <measurement group_id="O2" value="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis of risk difference (ABP 980 - Trastuzumab) estimated using a generalized linear model adjusted for the randomization stratification factors T-stage, node status, hormone receptor status, planned paclitaxel dosing schedule, and geographic region.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analyses of secondary endpoints were prespecified to be considered descriptive only.</non_inferiority_desc>
            <p_value>0.1086</p_value>
            <method>Generalized linear model</method>
            <method_desc>Generalized linear model adjusted for the randomization stratification factors.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>6.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>12.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis of risk ratio (ABP 980 / Trastuzumab) estimated using a generalized linear model adjusted for the randomization stratification factors T-stage, node status, hormone receptor status, planned paclitaxel dosing schedule, and geographic region.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analyses of secondary endpoints were prespecified to be considered descriptive only.</non_inferiority_desc>
            <p_value>0.0807</p_value>
            <method>Generalized linear model</method>
            <method_desc>Generalized linear model adjusted for the randomization stratification factors.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.1463</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0080</ci_lower_limit>
            <ci_upper_limit>1.3035</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Pathologic Complete Response in Breast Tissue and Axillary Lymph Nodes and Absence of DCIS</title>
        <description>Pathological complete response was defined as the absence of invasive tumor cells in the breast tissue and axillary lymph node(s) and absence of residual DCIS.
Participants underwent a lumpectomy or mastectomy with sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND) within 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase. The pathology evaluation of surgical specimens for pCR analysis was conducted by local laboratories at the study sites.</description>
        <time_frame>3 to 7 weeks after the last dose of study drug in the neoadjuvant phase</time_frame>
        <population>pCR evaluable population</population>
        <group_list>
          <group group_id="O1">
            <title>ABP 980</title>
            <description>Participants received ABP 980 at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Trastuzumab</title>
            <description>Participants received trastuzumab at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Pathologic Complete Response in Breast Tissue and Axillary Lymph Nodes and Absence of DCIS</title>
          <description>Pathological complete response was defined as the absence of invasive tumor cells in the breast tissue and axillary lymph node(s) and absence of residual DCIS.
Participants underwent a lumpectomy or mastectomy with sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND) within 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase. The pathology evaluation of surgical specimens for pCR analysis was conducted by local laboratories at the study sites.</description>
          <population>pCR evaluable population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="358"/>
                <count group_id="O2" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7"/>
                    <measurement group_id="O2" value="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis of risk difference (ABP 980 - Trastuzumab) estimated using a generalized linear model adjusted for the randomization stratification factors T-stage, node status, hormone receptor status, planned paclitaxel dosing schedule, and geographic region.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analyses of secondary endpoints were prespecified to be considered descriptive only.</non_inferiority_desc>
            <p_value>0.0253</p_value>
            <method>Generalized linear model</method>
            <method_desc>Generalized linear model adjusted for the randomization stratification factors.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>8.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.1</ci_lower_limit>
            <ci_upper_limit>13.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis of risk ratio (ABP 980 / Trastuzumab) estimated using a generalized linear model adjusted for the randomization stratification factors T-stage, node status, hormone receptor status, planned paclitaxel dosing schedule, and geographic region.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analyses of secondary endpoints were prespecified to be considered descriptive only.</non_inferiority_desc>
            <p_value>0.0245</p_value>
            <method>Generalized linear model</method>
            <method_desc>Generalized linear model adjusted for the randomization stratification factors.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.2746</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0673</ci_lower_limit>
            <ci_upper_limit>1.5222</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Neoadjuvant phase: From the first dose of study drug until 30 days after last dose in the neoadjuvant phase or until the start of the adjuvant phase, up to 16 weeks. Adjuvant phase: From the first dose of study drug after surgery until 30 days after last dose; approximately 40 weeks.</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Neoadjuvant Phase: ABP 980</title>
          <description>Participants received ABP 980 at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles.</description>
        </group>
        <group group_id="E2">
          <title>Neoadjuvant Phase: Trastuzumab</title>
          <description>Participants received trastuzumab at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles.</description>
        </group>
        <group group_id="E3">
          <title>Adjuvant Phase: ABP 980/ABP 980</title>
          <description>After surgery, participants initially randomized to ABP 980 continued to receive ABP 980 at a dose of 6 mg/kg IV infusion Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase.</description>
        </group>
        <group group_id="E4">
          <title>Adjuvant Phase: Trastuzumab/Trastuzumab</title>
          <description>After surgery, participants originally randomized to trastuzumab were re-randomized and continued to receive trastuzumab at a dose of 6 mg/kg IV infusion Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase.</description>
        </group>
        <group group_id="E5">
          <title>Adjuvant Phase: Trastuzumab/ABP 980</title>
          <description>After surgery, participants originally randomized to trastuzumab were re-randomized and switched to receive ABP 980 at a dose of 6 mg/kg IV infusion Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Gastrointestinal toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Drug dispensing error</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Wound decomposition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Metastases to adrenals</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="227" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="220" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="124" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="60" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radiation skin injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="361"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="349"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

